Genmab A (GMAB) Raw Materials (2023 - 2025)

Genmab A (GMAB) has reported Raw Materials for 3 consecutive years, with $6.0 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Raw Materials rose 360.62% year-over-year to $6.0 million; the trailing twelve-month figure through Dec 2025 stood at $6.0 million (up 360.62% YoY), and the FY2025 full-year result was $6.0 million, up 500.0% from the prior year.
• Raw Materials climbed to $6.0 million in Q4 2025 per GMAB's latest filing, from $1.3 million in the prior quarter.
• Across five years, Raw Materials topped out at $6.0 million in Q4 2025 and bottomed at $1.3 million in Q4 2024.
• Historically, Raw Materials has averaged $2.9 million across 3 years, with a median of $1.3 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Raw Materials slipped 0.96% in 2024, then soared 360.62% in 2025.
• Over 3 years, Raw Materials stood at $1.3 million in 2023, then slipped by 0.96% to $1.3 million in 2024, then jumped by 360.62% to $6.0 million in 2025.
• According to Business Quant data, Raw Materials over the past three periods registered $6.0 million, $1.3 million, and $1.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.